Efficacy of 5-aminosalicylates in crohn's disease: Systematic review and meta-analysis

American Journal of Gastroenterology

Volumn 106, Issue 4, 2011, Pages 617-629

  Ford, Alexander C ^a,b   Kane, Sunanda V ^c   Khan, Khurram J ^d   Achkar, Jean Paul ^e   Talley, Nicholas J ^f   Marshall, John K ^d   Moayyedi, Paul ^d  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c Mayo Clinic College of Medicine   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e LERNER RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; CORTICOSTEROID; MESALAZINE; OLSALAZINE; PLACEBO; RAFASSAL; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

CLINICAL ASSESSMENT; COCHRANE LIBRARY; COLON; CROHN DISEASE; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; EMBASE; EPIGASTRIC PAIN; HEADACHE; HEARTBURN; HUMAN; ILEUM; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CROHN DISEASE; HUMANS; MESALAMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; RISK REDUCTION BEHAVIOR; SULFASALAZINE; TREATMENT OUTCOME;

EID: 79953788479     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.71     Document Type: Review

References (45)

1. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathological clinical entity. JAMA 1932; 99: 1323-9.
2. Lofus CG, Lofus EV Jr, Harmsen WS et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Infamm Bowel Dis 2007;13:254-61. (Pubitemid 46465905)
3. Lofus EV Jr, Silverstein MD, Sandborn WJ et al. Crohn's disease in Olm-sted County, Minnesota, 1940-1993: incidence, prevalence, and survival. Gastroenterology 1999;116:1161-8.
4. Kappelman MD, Rifas-Shiman SL, Kleinman K et al The prevalence and geographic distribution of Crohn's disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol 2007; 5: 1424-9. (Pubitemid 350181588)
5. Greenberg GR, Feagan BG, Martin F et al Oral budesonide for active Crohn's disease. N Engl J Med 1994;331:836-41. (Pubitemid 24289710)
6. Lemann M, Mary J-Y, Duclos B et al Infiximab plus azathioprine for ster-oid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-61.
7. Summers RW, Switz DM, Sessions JT Jr et al. National cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1979;77:847-69. (Pubitemid 9242048)
8. Targan SR, Hanauer SB, van Deventer SJH et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor α for Crohn's disease. N Engl J Med 1997;337:1029-35.
9. Candy S, Wright J, Gerber M et al A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
10. Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. N Engl J Med 2000;342:1627-32. (Pubitemid 30341531)
11. Sutherland LR, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis (review). Cochrane Database Syst Rev 2006, CD00543.
12. Sutherland LR MacDonald JK. Oral5-aminosalicylic acid for maintenance of remission in ulcerative colitis (Review). Cochrane Database Syst Rev 2006, CD00544.
13. Rousseaux C, Lefebvre B, Dubuquoy L et al Intestinal antiInfammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med 2005;201:1205-15. (Pubitemid 40629065)
14. Prantera C, Pallone F, Brunetti G et al Oral5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. Gastroenterology 1992;103:363-8.
15. Rasmussen SN, Lauritsen K, Tage-Jensen U et al 5-Aminosalicylic acid in the treatment of Crohn's disease: a 16-week double-blind, placebo-control-led, multicentre study with Pentasa. Scand J Gastroenterol 1987;22:877-83. (Pubitemid 18041645)
16. Singleton JW, Hanauer SB, Gitnick GL et al Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993;104:1293-301. (Pubitemid 23235401)
17. Tomson ABR, Wright JP, Vatn M et al Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease. Aliment Pharmacol Ter 1995;9:673-83. (Pubitemid 26042105)
18. Wright JP Jewell DP Modigliani R et al A randomized, double-blind, placebo-controlled trial of olsalazine for active Crohn's disease. Infamm Bowel Dis 1995;1:241-6.
19. Akobeng AK, Gardener E. Oral5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease (review). Cochrane Data-base Syst Rev 2005, CD003715.
20. Camma C, Giunta M, Rosselli M et al. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73. (Pubitemid 27461232)
21. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-88. (Pubitemid 38561234)
22. Messori A, Brignola C, Trallori G et al. effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89:692-8. (Pubitemid 24132048)
23. Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89:2116-24. (Pubitemid 24363653)
24. Steinhart AH, Forbes A, Mills EC et al Systematic review: the potential in-f uence of mesalazine formulation on maintenance of remission in Crohn's disease. Aliment Pharmacol Ter 2007;25:1389-99. (Pubitemid 46848885)
25. Ford AC, Guyatt GH, Tal ley NJ et al Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. Am J Gastroenterol 2010;105:280-8.
26. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions: Version 5.0.2 [updated September 2009]. http://www.cochrane- handbook.org. Accessed April 2010.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88. (Pubitemid 17189972)
28. Higgins JPT, Tompson SG, Deeks JJ et al Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-60. (Pubitemid 37088507)
29. Tegger M, Davey-Smith G, Schneider M et al Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997; 315: 629-34. (Pubitemid 27387172)
30. Mahida YR, Jewell DP Slow release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990;45:88-92. (Pubitemid 20151606)
31. Tremaine WJ, Schroeder KW, Jarrison JM et al A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994; 19: 278-82. (Pubitemid 24371047)
32. Lennard-Jones JE. Sulphasalazine in asymptomatic Crohn's disease. Gut 1977;18:69-72.
33. Wellmann W, Schroder U. New oral preparations for maintenance therapy in Crohn's disease. Can J Gastroenterol1988;2 (Suppl A): 71A-2A.
34. International Mesalazine Study Group. Coated oral5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ter 1990;4:55-64.
35. Gendre J-P, Mary J-Y, Florent C et al. Oral mesalamine (Pentasa) as mainte-nance treatment in Crohn's disease: a multicenter placebo-controlled study Gastroenterology 1993;104:435-9. (Pubitemid 23033415)
36. Arber N, Odes S, Fireman Z et al A controlled double blind multicenter study of the effectiveness of 5-aminosalicylic acid in patients with Crohn's disease in remission. J Clin Gastroenterol 1995;20:203-6.
37. Modigliani R, Colombel J-F, Dupas J-L et al Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance. Gastroenterology 1996; 110: 688-93. (Pubitemid 26075447)
38. De Franchis R Omodei P, Ranzi Tet al Controlled trial oforal5-aminosalicylic acid for the prevention of early relapse in Crohn's disease. Aliment Pharmacol Ter 1997;11:845-52. (Pubitemid 27445669)
39. Sutherland LR, Martin F, Bailey RJ et al. A randomized, placebo-control-led, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. Gastroenterology 1997;112:1069-77. (Pubitemid 27157516)
40. Mahmud N, Kamm MA, Dupas J-L et al Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ile-ocolitis: a double blind, parallel, randomised, multicentre study Gut 2001;49:552-6. (Pubitemid 32896987)
41. Bondesen S, the Danish 5-ASA Group. Mesalazine (Pentasa) as prophylaxis in Crohn's disease. A multicenter, controlled trial. Scand J Gastroenterol 1991;26:68.
42. Bresci G, Parisi G, Banti S. Long-term therapy with 5-aminosalicylic acid in Crohn's disease: is it useful? Our experience. Int J Clin Pharm Res 1994;14:133-8.
43. Singleton JW, Summers RW, Kern F Jr et al. A trial of sulfasala-zine as adjunctive therapy in Crohn's disease. Gastroenterology 1979; 77: 887-97. (Pubitemid 9242051)
44. Malchow M, Ewe K, Brandes JW et al. European cooperative Crohn's disease study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66. (Pubitemid 14218578)
45. Colombel J-F, Sandborn WJ, Reinisch W et al Infiximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362: 1383-95.